Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis Publication Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis This study evaluated the pharmacokinetics (PK) and pharmacokinetic–pharmacodynamic (PK–PD) relationship of clazakizumab, an anti–interleukin-6 (IL-6)…Danielle Pillsbury2026 年 3 月 24 日
From Numbers to Narrative: Mastering the Art of PK Presentation Guide From Numbers to Narrative: Mastering the Art of PK Presentation Master PK data reporting with a structured guide to presenting pharmacokinetic results clearly and turning…Certara2026 年 3 月 20 日
What are Common Bioequivalence Study Mistakes? 博客 What are Common Bioequivalence Study Mistakes? Learn about the most common bioequivalence study mistakes drug developers make and the differences between…Certara2026 年 3 月 20 日
Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Certara2026 年 3 月 9 日
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…Certara2026 年 3 月 6 日
Understanding and Calculating Steady State Pharmacokinetics BlogKnowledge Base Understanding and Calculating Steady State Pharmacokinetics Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…Certara2026 年 3 月 5 日
Phoenix Roadshow 2026 – Raleigh/Durham Live Events Phoenix Roadshow 2026 – 美国罗利-达勒姆 Certara2026 年 3 月 2 日